Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) (AA 1-111) antibody

Details for Product No. ABIN393528
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms Vhlh, HRCA1, RCA1, VHL1, pVHL
Epitope
AA 1-111
(8), (7), (6), (4), (4), (3), (3), (2), (2), (1), (1), (1)
Reactivity
Human
(78), (42), (40), (15), (12)
Host
Mouse
(58), (21), (6)
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
(4), (4), (3), (3), (3), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Application
ELISA, Western Blotting (WB)
(58), (30), (22), (14), (10), (5), (4), (3), (3), (1), (1)
Pubmed 5 references available
Quantity 0.1 mg
Options
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN393528
450.00 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen VHL (NP_000542, 1 a.a. ~ 111 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 K
Clone 1G12
Isotype IgG2b kappa
Specificity VHL (NP_000542, 1 a.a. ~ 111 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Purification This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Alternative Name VHL
Background Synonyms: Serine protease inhibitor J6, 47 kDa heat shock protein, Collagen-binding protein, Colligin, Serpin H1,Hsp47, Cbp1, Serpinh1
Molecular Weight 24153 DA
Gene ID 12406
NCBI Accession NP_000542
Research Area Ubiquitin-related antibodies, Protein Modifications, Cancer, Transcription Factors, Cell Structure
Application Notes ELISA ~~ 1ug/ml~3ng/ml Western blot ~~ 1:500~1000
Comment

Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Restrictions For Research Use only
Buffer PBS with 0.09% (w/v) sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Supplier Images
anti-Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) (AA 1-111) antibody Detection limit for recombinant GST tagged VHL is approximately 0.1 ng/mL as a capture antibody.
Background publications Montani, Heinimann, von Teichman et al.: "VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease." in: The American journal of surgical pathology, Vol. 34, Issue 6, pp. 806-15, 2010 (PubMed).

Chacon-Camacho, Rodriguez-Dennen, Camacho-Molina et al.: "Clinical and molecular features of familial and sporadic cases of von Hippel-Lindau disease from Mexico." in: Clinical & experimental ophthalmology, Vol. 38, Issue 3, pp. 277-83, 2010 (PubMed).

Liu, Wu, Chen et al.: "A Large-scale genetic association study of esophageal adenocarcinoma risk." in: Carcinogenesis, Vol. 31, Issue 7, pp. 1259-63, 2010 (PubMed).

Bailey, Xie, Do et al.: "Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study." in: Diabetes Care, Vol. 33, Issue 10, pp. 2250-3, 2010 (PubMed).

Peña, Lathia, Shan et al.: "Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 16, Issue 19, pp. 4853-63, 2010 (PubMed).

Validation Images
Did you look for something else?
back to top